# Tanabe Pharma Corporation clinical trials: 132 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 132 trials with Tanabe Pharma Corporation as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tanabe Pharma Corporation: 132 rows for $6.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tanabe-pharma-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 132
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 132, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 28, 2026 | NCT07793513 | Study of BK1803 in Healthy Infants | Tanabe Pharma Corporation | Phase 3 | Recruiting | Pertussis, Diphtheria, Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793513) |
| May 29, 2025 | NCT06994286 | The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects. | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994286) |
| July 1, 2024 | NCT06482346 | Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy Adult Male Volunteers | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482346) |
| January 9, 2024 | NCT06196905 | An Exploratory Study of MT-2990 in Patients With AAV | Tanabe Pharma Corporation | Phase 1 | Completed | Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV) | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06196905) |
| December 20, 2022 | NCT05658562 | A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL | Tanabe Pharma Corporation | Phase 1/2 | Active not recruiting | Diffuse Large B-Cell Lymphoma | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05658562) |
| May 31, 2022 | NCT05396235 | A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy Adult Males | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05396235) |
| February 15, 2022 | NCT05240612 | A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) | Tanabe Pharma Corporation | Phase 1 | Completed | HTLV-1-Associated Myelopathy (HAM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05240612) |
| January 20, 2022 | NCT05198557 | A Study of MT-0551 in Patients With Systemic Sclerosis | Tanabe Pharma Corporation | Phase 3 | Active not recruiting | Systemic Sclerosis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198557) |
| November 17, 2021 | NCT05123196 | Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy | Tanabe Pharma Corporation | Phase 2 | Completed | Painful Diabetic Peripheral Neuropathy | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05123196) |
| March 27, 2019 | NCT03891758 | Confirmatory Study of BK1310 in Healthy Infants | Tanabe Pharma Corporation | Phase 3 | Completed | Tetanus, Diphtheria, Pertussis, Poliomyelitis, Bacterial Meningitis | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03891758) |
| August 24, 2018 | NCT03645863 | Effects of Iron Supplements on the Pharmacokinetics of MT-6548 | Tanabe Pharma Corporation | Phase 3 | Completed | Healthy | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03645863) |
| June 27, 2018 | NCT03570957 | A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients | Tanabe Pharma Corporation | Phase 1 | Completed | Seasonal Allergic Rhinitis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03570957) |
| April 25, 2018 | NCT03507738 | Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03507738) |
| March 9, 2018 | NCT03461146 | Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney... | Tanabe Pharma Corporation | Phase 3 | Completed | Anemia; Hemodialysis Dependent Chronic Kidney Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03461146) |
| February 20, 2018 | NCT03439137 | Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney... | Tanabe Pharma Corporation | Phase 3 | Completed | Anemia; Hemodialysis Dependent Chronic Kidney Disease | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03439137) |
| February 19, 2018 | NCT03436693 | Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy | Tanabe Pharma Corporation | Phase 3 | Completed | Diabetic Nephropathy | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03436693) |
| January 18, 2018 | NCT03402386 | Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan | Tanabe Pharma Corporation | Phase 3 | Completed | Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03402386) |
| November 1, 2017 | NCT03329196 | Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan | Tanabe Pharma Corporation | Phase 3 | Completed | Anemia; Non-dialysis Dependent Chronic Kidney Disease | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329196) |
| August 10, 2017 | NCT03245008 | Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain | Tanabe Pharma Corporation | Phase 2/3 | Completed | Osteoarthritis, Knee / Osteoarthritis, Hip | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03245008) |
| June 15, 2017 | NCT03188692 | Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants | Tanabe Pharma Corporation | Phase 3 | Completed | Immunization | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03188692) |
| June 5, 2017 | NCT03176771 | Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia | Tanabe Pharma Corporation | Phase 2/3 | Completed | Tardive Dyskinesia | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03176771) |
| June 1, 2017 | NCT03172598 | Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy | Tanabe Pharma Corporation | Phase 2 | Completed | Painful Diabetic Peripheral Neuropathy | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03172598) |
| May 17, 2017 | NCT03156738 | A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy... | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03156738) |
| December 14, 2016 | NCT02992925 | Phase 3 Study of BK1310 in Healthy Infants | Tanabe Pharma Corporation | Phase 3 | Completed | Immunization; Infection | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02992925) |
| November 2, 2016 | NCT02953132 | A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers | Tanabe Pharma Corporation | Phase 1 | Completed | Healthy | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02953132) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 1/2 | 4 |
| Phase 2 | 25 |
| Phase 2/3 | 7 |
| Phase 3 | 62 |
| Phase 4 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 123 |
| Terminated | 6 |
| Active not recruiting | 2 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 24 |
| Renal Insufficiency, Chronic | 13 |
| Insulin Resistance | 11 |
| Hepatitis C, Chronic | 11 |
| Hyperphosphatemia | 10 |
| Diabetic Nephropathies | 7 |
| Schizophrenia | 6 |
| Mental Disorders | 5 |
| Haemophilus Infections | 5 |
| Crohn Disease | 5 |
| Multiple Sclerosis, Relapsing-Remitting | 5 |
| Dyslipidemias | 4 |
| Anemia | 4 |
| Cerebral Infarction | 4 |
| Hepatitis C | 4 |
| Tetanus | 3 |
| Diphtheria | 3 |
| Whooping Cough | 3 |
| Rhinitis, Allergic, Perennial | 3 |
| Poliomyelitis | 2 |
| Peripheral Vascular Diseases | 2 |
| Kidney Diseases | 2 |
| Stroke | 2 |
| Brain Ischemia | 2 |
| Psoriasis | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
